Role of a selective aldosterone blocker in mice with chronic heart failure

Journal of Cardiac Failure

Volumn 10, Issue 1, 2004, Pages 67-73

  Wang, Dahai ^a   Liu, Yun He ^a   Yang, Xiao Ping ^a   Rhaleb, Nour Eddine ^a   Xu, Jiang ^a   Peterson, Edward ^a   Rudolph, Amy E ^b   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Cardiac function; echocardiography; remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; INTERSTITIUM; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIAC OUTPUT; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; MICE; MICE, INBRED C57BL; MUSCLE CELLS; MYOCARDIAL INFARCTION; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 3042792357     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(03)00578-5     Document Type: Article

References (35)

1. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J. Jr., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., Klein M., Lamas G.A., Packer M., Rouleau J., Rouleau J.L., Rutherford J., Wertheimer J.H., Hawkins C.M., on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med. 327:1992;669-677
2. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., Deedwania P.C., Ney D.E., Snavely D.B., Chang P.I., on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752
3. Rudolph A.E., Blasi E.R., Delyani J.A. Tissue-specific corticosteroidogenesis in the rat. Mol Cell Endocrinol. 165:2000;221-224
4. Weber K.T. Aldosterone and spironolactone in heart failure. [editorial] N Engl J Med. 341:1999;753-755
5. Cha A.J., Malecha S.E., Judge K.W. Aldosterone, a new appreciation of its role in heart failure. Pharmacotherapy. 20:2000;1107-1115
6. Ward M.R., Kanellakis P., Ramsey D., Funder J., Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 104:2001;467-472
7. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L., [for the CONSENSUS Trial Study Group]. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 82:1990;1730-1736
8. Pitt B., Zannad F., Remme W., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:1999;709-717
9. de Gasparo M., Joss U., Ramjoue H.P., Whitebread S.E., Haenni H., Schenkel L., Kraehenbuehl C., Biollaz M., Grob J., Schmidlin J., Wieland P., Wehrli H.U. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 240:1987;650-656
10. Struthers A.D. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 16:(Suppl N):1995;103-106
11. Yang F., Liu Y.-H., Yang X.-P., Xu J., Kapke A., Carretero O.A. Myocardial infarction and cardiac remodelling in mice. Exp Physiol. 87:2002;547-555
12. 2 kinin receptor gene knockout mice. Circ Res. 88:2001;1072-1079
13. Krege J.H., Hodgin J.B., Hagaman J.R., Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 25:1995;1111-1115
14. Yang X.-P., Liu Y.-H., Rhaleb N.-E., Kurihara N., Kim H.E., Carretero O.A. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 277:1999;H1967-H1974
15. Liu Y.-H., Yang X.-P., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol. 272:1997;H722-H727
16. Liu Y.-H., Yang X.-P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. 99:1997;1926-1935
17. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 33:1993;40-45
18. Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J. 16:(Suppl N):1995;107-110
19. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:2003;1309-1321
20. Wolny A., Clozel J.-P., Rein J., Mory P., Vogt P., Turino M., Kiowski W., Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 80:1997;219-227
21. Hojo Y., Ikeda U., Katsuki T., Mizuno O., Fujikawa H., Shimada K. Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation. Heart. 83:2000;574-576
22. 12] angiotensin I in human dorsal hand veins. In vivo demonstration of non-ACE production of angiotensin II in humans. Circulation. 104:2001;1805-1808
23. Balcells E., Meng Q.C., Johnson W.H. Jr., Oparil S., Dell'Italia L.J. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 273:1997;H1769-H1774
24. Brilla C.G., Weber K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 26:1992;671-677
25. Duprez D.A., Bauwens F.R., De Buyzere M.L., De Backer T.L., Kaufman J.M., Van Hoecke J., Vermeulen A., Clement D.L. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 71:1993;17A-20A
26. Rocha R., Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 970:2002;89-100
27. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 143:2002;4828-4836
28. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A.G., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 283:2002;H1802-H1810
29. Pitt B., Reichek N., Metscher B., Phillips R., Roniker B., Kleiman J., Burns D. Efficacy and safety of eplerenone, enalapril and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. (abstract) Am J Hypertens. 15:2002;23A
30. Delyani J.A., Robinson E.L., Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 281:2001;H647-H654
31. Rocha R., Stier C.T. Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 12:2001;308-314
32. Suzuki G., Morita H., Sharov V.G., Todor A., Goldstein S., Sabbah H.N. Blockade of aldosterone receptors with eplerenone prevents progressive left ventricular dysfunction and attenuates remodeling in dogs with heart failure. [abstract] Circulation. 104:2002;II-519
33. 1 antagonist, and combined treatment in mice with heart failure. J Cardiovasc Pharmacol. 36:2000;472-480
34. Liu Y.-H., Xu J., Yang X.-P., Yang F., Shesely E., Carretero O.A. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension. 39:2001;375-381
35. 2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 30:1997;735-740